These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 35056993)

  • 1. Making Sense of Antisense Oligonucleotide Therapeutics Targeting Bcl-2.
    Gagliardi M; Ashizawa AT
    Pharmaceutics; 2022 Jan; 14(1):. PubMed ID: 35056993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eradication of human non-Hodgkin's lymphoma in SCID mice by BCL-2 antisense oligonucleotides combined with low-dose cyclophosphamide.
    Klasa RJ; Bally MB; Ng R; Goldie JH; Gascoyne RD; Wong FM
    Clin Cancer Res; 2000 Jun; 6(6):2492-500. PubMed ID: 10873104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of apoptosis and enhancement of chemosensitivity in human prostate cancer LNCaP cells using bispecific antisense oligonucleotide targeting Bcl-2 and Bcl-xL genes.
    Yamanaka K; Rocchi P; Miyake H; Fazli L; So A; Zangemeister-Wittke U; Gleave ME
    BJU Int; 2006 Jun; 97(6):1300-8. PubMed ID: 16686729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hematologic malignancies: newer strategies to counter the BCL-2 protein.
    Ebrahim AS; Sabbagh H; Liddane A; Raufi A; Kandouz M; Al-Katib A
    J Cancer Res Clin Oncol; 2016 Sep; 142(9):2013-22. PubMed ID: 27043233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted antisense radiotherapy and dose fractionation using a (177)Lu-labeled anti-bcl-2 peptide nucleic acid-peptide conjugate.
    Liu D; Balkin ER; Jia F; Ruthengael VC; Smith CJ; Lewis MR
    Nucl Med Biol; 2015 Sep; 42(9):704-10. PubMed ID: 26081917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oblimersen sodium (G3139 Bcl-2 antisense oligonucleotide) therapy in Waldenstrom's macroglobulinemia: a targeted approach to enhance apoptosis.
    Frankel SR
    Semin Oncol; 2003 Apr; 30(2):300-4. PubMed ID: 12720157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bcl-xL antisense oligonucleotide and cisplatin combination therapy extends survival in SCID mice with established mesothelioma xenografts.
    Littlejohn JE; Cao X; Miller SD; Ozvaran MK; Jupiter D; Zhang L; Rodarte C; Smythe WR
    Int J Cancer; 2008 Jul; 123(1):202-8. PubMed ID: 18360826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pro-apoptotic therapy with the oligonucleotide Genasense (oblimersen sodium) targeting Bcl-2 protein expression enhances the biological anti-tumour activity of rituximab.
    Ramanarayanan J; Hernandez-Ilizaliturri FJ; Chanan-Khan A; Czuczman MS
    Br J Haematol; 2004 Dec; 127(5):519-30. PubMed ID: 15566355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells.
    Yamanaka K; Rocchi P; Miyake H; Fazli L; Vessella B; Zangemeister-Wittke U; Gleave ME
    Mol Cancer Ther; 2005 Nov; 4(11):1689-98. PubMed ID: 16275990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bcl-2 antisense in the treatment of human malignancies: a delusion in targeted therapy.
    Gjertsen BT; Bredholt T; Anensen N; Vintermyr OK
    Curr Pharm Biotechnol; 2007 Dec; 8(6):373-81. PubMed ID: 18289046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment.
    Klasa RJ; Gillum AM; Klem RE; Frankel SR
    Antisense Nucleic Acid Drug Dev; 2002 Jun; 12(3):193-213. PubMed ID: 12162702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the expression of anti-apoptotic proteins by antisense oligonucleotides.
    Delihas N
    Curr Drug Targets; 2001 Jun; 2(2):167-80. PubMed ID: 11469717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination bcl-2 antisense and radiation therapy for nasopharyngeal cancer.
    Yip KW; Mocanu JD; Au PY; Sleep GT; Huang D; Busson P; Yeh WC; Gilbert R; O'Sullivan B; Gullane P; Bastianutto C; Liu FF
    Clin Cancer Res; 2005 Nov; 11(22):8131-44. PubMed ID: 16299246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bcl-2 antisense therapy in B-cell malignancies.
    Chanan-Khan A
    Blood Rev; 2005 Jul; 19(4):213-21. PubMed ID: 15784299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Making sense of antisense.
    Vidal L; Blagden S; Attard G; de Bono J
    Eur J Cancer; 2005 Dec; 41(18):2812-8. PubMed ID: 16289851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Copper-64-labeled anti-bcl-2 PNA-peptide conjugates selectively localize to bcl-2-positive tumors in mouse models of B-cell lymphoma.
    Jia F; Balaji BS; Gallazzi F; Lewis MR
    Nucl Med Biol; 2015 Nov; 42(11):809-15. PubMed ID: 26239085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells.
    Derenne S; Monia B; Dean NM; Taylor JK; Rapp MJ; Harousseau JL; Bataille R; Amiot M
    Blood; 2002 Jul; 100(1):194-9. PubMed ID: 12070027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antisense oligonucleotides directed at the bcl-xl gene product augment chemotherapy response in mesothelioma.
    Ozvaran MK; Cao XX; Miller SD; Monia BA; Hong WK; Smythe WR
    Mol Cancer Ther; 2004 May; 3(5):545-50. PubMed ID: 15141012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oligonucleotide Therapy for Obstructive and Restrictive Respiratory Diseases.
    Liao W; Dong J; Peh HY; Tan LH; Lim KS; Li L; Wong WF
    Molecules; 2017 Jan; 22(1):. PubMed ID: 28106744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antisense Oligonucleotides Targeting Y-Box Binding Protein-1 Inhibit Tumor Angiogenesis by Downregulating Bcl-xL-VEGFR2/-Tie Axes.
    Setoguchi K; Cui L; Hachisuka N; Obchoei S; Shinkai K; Hyodo F; Kato K; Wada F; Yamamoto T; Harada-Shiba M; Obika S; Nakano K
    Mol Ther Nucleic Acids; 2017 Dec; 9():170-181. PubMed ID: 29246296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.